BeiGene
BGNE
$179.87
Share price
-2.33%
Change (1 day)
5.98%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Operating Margin for BeiGene (BGNE)
Operating Margin as of September 2023 (TTM): -88.19%
According to BeiGene 's latest financial reports and stock price the company's current Operating Margin is -88.19%. At the end of 2022 the company had an Operating Margin of -138.50%.
Operating Margin history for BeiGene from 2015 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | -138.50% | 13.25% |
| 2021 | -122.30% | -76.66% |
| 2020 | -523.90% | 137.75% |
| 2019 | -220.35% | -36.68% |
| 2018 | -348.01% | 811.02% |
| 2017 | -38.20% | -99.66% |
| 2016 | -11,136.73% | 1619.4% |
| 2015 | -647.71% | 355.24% |
| 2014 | -142.28% | 100.93% |
| 2013 | -70.81% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -36.36% | -58.77% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -8,391.15% | 9,414.85% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.